Deciphera Pharmaceuticals, Inc. (DCPH) News

Deciphera Pharmaceuticals, Inc. (DCPH): $13.92

0.28 (+2.05%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DCPH to Watchlist
Sign Up

Industry: Biotech


Ranked

of 401

in industry

Filter DCPH News Items

DCPH News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

DCPH News Highlights

  • For DCPH, its 30 day story count is now at 14.
  • Over the past 10 days, the trend for DCPH's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
  • The most mentioned tickers in articles about DCPH are BEAT, DRUG and MSCI.

Latest DCPH News From Around the Web

Below are the latest news stories about Deciphera Pharmaceuticals Inc that investors may wish to consider to help them evaluate DCPH as an investment opportunity.

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

No summary available.

Seeking Alpha | February 11, 2022

Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steve Hoerter on Q4 2021 Results - Earnings Call Transcript

Deciphera Pharmaceuticals, Inc. (DCPH) Q4 2021 Earnings Conference Call February 08, 2022, 04:30 PM ET Company Participants Maghan Meyers - SVP, Argot Partners Steve Hoerter - President and CEO Dan Martin - Chief Commercial Officer Tucker Kelly - CFO Conference Call Participants Jessica Fye - JPMorgan Eun Yang - Jefferies...

SA Transcripts on Seeking Alpha | February 9, 2022

H.C. Wainwright Thinks Deciphera Pharmaceuticals’ Stock is Going to Recover

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Deciphera Pharmaceuticals (DCPH – Research Report), with a price target of $15.00. The company's shares closed last Tuesday at $8.16, close to its 52-week low of $7.36. According to TipRanks.com, Fein has 0 stars on 0-5 stars ranking scale with an average return of -2.4% and a 36.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals, Inc., and Global Blood Therapeutics. Deciphera Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $13.75.

Brian Anderson on TipRanks | February 9, 2022

Deciphera (DCPH) Q4 Loss Wider Than Expected, Revenues Beat

Deciphera (DCPH) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock down is after-hours trading.

Yahoo | February 9, 2022

Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the fourth quarter and year ended December 31, 2021, and provided a corporate update. “I am immensely proud of our organization’s achievements in 2021 and believe that we are well positioned for long-term success as we work towards our expected milestones in 2022,” said Steve Hoerter, President and Chief Executive Officer of Deciphera Pharmaceuticals. “While the unexpected result

Business Wire | February 8, 2022

Deciphera Pharmaceuticals GAAP EPS of -$1.51 misses by $0.03, revenue of $24.2M beats by $0.92M

Deciphera Pharmaceuticals press release (DCPH): Q4 GAAP EPS of -$1.51 misses by $0.03.Revenue of $24.2M (+24.2% Y/Y) beats by $0.92M.

Seeking Alpha | February 8, 2022

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Tops Revenue Estimates

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -1.34% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 8, 2022

CIBC Asset Management Inc Buys Bank of Nova Scotia, Franco-Nevada Corp, Suncor Energy Inc, ...

Toronto, A6, based Investment company CIBC Asset Management Inc (Current Portfolio) buys Bank of Nova Scotia, Franco-Nevada Corp, Suncor Energy Inc, NVIDIA Corp, iShares MSCI EAFE ETF, sells Shaw Communications Inc, Progressive Corp, Visa Inc, Allegion PLC, Lightspeed Commerce Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, CIBC Asset Management Inc.

Yahoo | February 8, 2022

Drug/Biotech Stock Q4 Earnings Due Feb 8: PFE, INCY & DCPH

Let us take a look at three biotech/drug companies that are slated to release quarterly results on Feb 8.

Yahoo | February 7, 2022

Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

WALTHAM, Mass., February 02, 2022--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present virtually at the following investor conferences:

Yahoo | February 2, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.743 seconds.